Targeting angiogenesis in metastatic breast cancer

Oncologist

Volumn 17, Issue 8, 2012, Pages 1014-1026

  Reddy, Sangeetha ^a   Raffin, Michael ^b   Kaklamani, Virginia ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Fishawack Communications   (United States)

Author keywords

Angiogenesis; Bevacizumab; Everolimus; Metastatic breast cancer; Sorafenib; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CEDIRANIB; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEMCITABINE; LAPATINIB; LETROZOLE; MOTESANIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; BREAST METASTASIS; DESQUAMATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LEUKOPENIA; LOADING DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INDOLES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PACLITAXEL; PHENYLUREA COMPOUNDS; PYRROLES; SIROLIMUS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865227347     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0043     Document Type: Article

References (133)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011.
2. American Cancer Society. Breast cancer survival rates by stage. Available at: http://www.cancer.org/Cancer/ BreastCancer/DetailedGuide/breast-cancer-survival-bystage. Accessed November 16, 2011.
3. Chia SK, Speers CH, D'Yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
4. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004;100:44-52.
5. Arveux P, Grosclaude P, Reyrat E, et al. Breast cancer survival in France: A relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centers between 1980 and 1999. Proc Am Soc Clin Oncol 2003;22:Abstract 3437.
6. Gennari A, Conte P, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750.
7. Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009:CD003372.
8. Joensuu H, Holli K, HeikkinenMet al. Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 1998;16:3720-3730.
9. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
10. Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20: 616-624.
11. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-1816.
12. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-124.
13. Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-15.
14. Ellard SL, Clemons M, Gelmon KA et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. J Clin Oncol 2009;27:4536-4541.
15. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapyrefractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-1074.
16. Ding Q, Huo L, Yang JY et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-6117.
17. Merz M, Komljenovic D, Zwick S et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-286.
18. Bonelli MA, Fumarola C, Alfieri RR et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 2010;124:79-88
19. Tokunaga E, Kataoka A, Kimura Y et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006;42:629-635.
20. Kirkegaard T, Witton CJ, McGlynn LM et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005;207:139-146.
21. Wang L, Zhang Q, Zhang J, et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011;11:11:248.
22. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly-(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010;70:7970-7980.
23. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-214.
24. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011;29:373-374.
25. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29(15 suppl):Abstract 1007.
26. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-1790.
27. Banerjee S, Dowsett M, Ashworth A et al. Mechanisms of disease: Angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007;4:536-550.
28. Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007;9:216-226.
29. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
30. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
31. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
32. Alsina M, Ruiz-Echarri M, Capdevila J et al. Biomarkers for therapies directed at angiogenesis. Curr Colorectal Cancer Rep 2010;6:133-143.
33. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis 2010;13:1-14.
34. Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011;2:80-93.
35. Giamas G, Man YL, Hirner H et al. Kinases as targets in the treatment of solid tumors. Cell Signal 2010;22:984-1002.
36. Borgstrom P, Hillan KJ, Sriramarao P et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
37. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
38. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
39. O'Connor JP, Carano RA, Clamp AR et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: Insights from imaging. Clin Cancer Res 2009;15:6674-6682.
40. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-799.
41. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
42. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-3247.
43. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
44. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(15 suppl):Abstract 1005.
45. Brufsky AM, Hurvitz S, Perez E et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for secondline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-4293.
46. Gianni L, Romieu G, Lichinitser M et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)_docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Presented at the 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011.
47. Cuppone FBE, Vaccaro V, Puglisi F et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011;30:54.
48. O'Shaughnessy J, Miles D, Gray RJ et al. A metaanalysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010;28(15 suppl): Abstract 1005.
49. Cortes J, Calvo V, Ramirez-Merino N et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis. Ann Oncol 2012;23(5):1130-1137.
50. Lenzer J. FDA committee votes to withdraw bevacizumab for breast cancer. BMJ 2011;343:d4244.
51. Burstein HJ. Bevacizumab for advanced breast cancer: All tied up with a RIBBON? J Clin Oncol 2011;29:1232-1235.
52. European Medicines Agency. EPAR summary for the public: Avastin. Available at: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Summary_ for_the_public/human/000582/WC500029260.pdf. Accessed November 16, 2011.
53. Brufsky A, Valero V, Tiangco B et al. Second-line bevacizumab-containing therapy in patients with triplenegative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133: 1067-1075.
54. O'Shaughnessy J, Romieu G, Dieras V et al. Metaanalysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2011;70(24 suppl):P6-12-03.
55. Salvador J, Ciruelos E, Codes dVM et al. AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER-2 negative recurrent or metastatic BC: PFS analysis. Cancer Res 2012;71(24 suppl):P1-14-03.
56. De la Haba-Rodriguez JR, von MG, MartinMet al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The LEA study. Cancer Res 2012;71(24 suppl):OT3-01-15.
57. Lam S, de Groot S, Honkoop A et al. Combination of paclitaxel and bevacizumab without or with capecitabine as first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): First results from a randomized, multicenter, open-label, phase II study of the Dutch Breast Cancer Trialists' Group (BOOG). Cancer Res 2012;71(24 suppl):PD07-07.
58. Viens P, Petit T, Dalenc F et al. P4-20-01: Multicentric phase II PACS 09/Beverly1 Trial: First efficacy and safety results of neoadjuvant chemotherapy combined with bevacizumab in HER2-negative patients with non-metastatic inflammatory breast cancer. Cancer Res 2012;71(24 suppl):P4-20-01.
59. von Minckwitz G, Eidtmann H, RezaiMet al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309.
60. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-320.
61. Pierga JY, Petit T, Delozier T et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): An open-label, single-arm phase 2 study. Lancet Oncol 2012;13:375-384.
62. Mayer E, Ligibel J, Burstein H et al. OT3-02-04: TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. Cancer Res 2012;71(24 suppl):OT3-02-04.
63. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr Med Chem 2008;15:422-432.
64. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib:Areview of clinical data and perspectives in advanced solid tumors. The Oncologist 2008;13:845-858.
65. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-548.
66. Sweeney CJ, Chiorean EG, Verschraegen CF et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010;28: 4513-4520.
67. Faivre S, Demetri G, Sargent W et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745.
68. Kozloff M, Chuang E, Starr A et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436-1441.
69. Robert F, Sandler A, Schiller JH et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: A phase I dose-escalation study. Cancer Chemother Pharmacol 2010;66:669-680.
70. Barrios CH, Liu MC, Lee SC et al. Phase III ran-domized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121-131.
71. Bergh J, Bondarenko IM, Lichinitser MR et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 2012;30:921-929.
72. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010;28(7 suppl):Abstract LBA1011.
73. Robert NJ, Saleh MN, Paul D et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for firstline treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011;11:82-92.
74. Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140.
75. Hasskarl J. Sorafenib: Recent results. Cancer Res 2010;184:61-70.
76. Isaacs C, Herbolsheimer P, Liu MC et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-143.
77. Baselga J, Segalla JG, Roche H, et al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30(13):1484-1491.
78. Gradishar W, Kaklamani V, Prasad Sahoo T et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a firstline therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009.
79. Bondarde S, Kaklamani V, Prasad Sahoo T, et al. Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: Overall survival results from a doubleblind, randomized, placebo-controlled, phase 2b trial. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
80. Hudis C, Tauer KW, Hermann RC et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). Presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011.
81. Mariani G, Burdaeva O, Roman L et al. A doubleblind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer. Presented at the European Multidisciplinary Congress, Stockholm, Sweden, September 23-27, 2011.
82. Baselga J, Schwartzberg LS, Petrenciuc O, et al. Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). Presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7,2011.
83. Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-1372.
84. Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov 2009;8:535-536.
85. Bachelot T, Bourgier C, Cropet C et al. TAMRAD: A GINECO randomized phase ii trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 2011; 70(24 suppl):Abstract S1-6.
86. Baselga J, Campone M, PiccartMet al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011;366:520-529.
87. ClinicalTrials. gov. Everolimus in combination with trastuzumab and paclitaxel in the treatment of HER2 positive locally advanced or metastatic breast cancer (BOLERO-1). Available at: http://www. clinicaltrials.gov/show/NCT00876395. Accessed November 8, 2011.
88. ClinicalTrials. gov. Daily everolimus in combination with trastuzumab and vinorelbine in HER2/Neu positive women with locally advanced or metastatic breast cancer (BOLERO-3). Available at: http://www. clinicaltrials.gov/ct2/show/NCT01007942. Accessed November 8, 2011.
89. Morrow PK, Wulf GM, Ensor J et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumabbased therapy. J Clin Oncol 2011;29:3126-3132.
90. Jerusalem G, Fasolo A, Dieras V et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011;125:447-455.
91. Andre F, Campone M, O'Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28:5110-5115.
92. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91.
93. Dalenc F, Campone M, Hupperets P et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial. J Clin Oncol 2010;28(15 suppl):Abstract 1013.
94. Rugo HS, Stopeck AT, Joy AA et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-2465.
95. Martin M, Roche H, Pinter T et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011;12:369-376.
96. Taylor SK, Chia S, Dent S et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the Princess Margaret Hospital Phase II Consortium. The Oncologist 2010;15: 810-818.
97. Slamon D, Gomez H, Kabbinavar FF, Amit O et al. Randomized study of pazopanib lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008;26(15 suppl): Abstract 1016.
98. Miller KD, Trigo JM, Wheeler C et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11:3369-3376.
99. Boer K, Lang I, Llombart-Cussac A et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind, placebocontrolled, randomized phase II study. Invest New Drugs 2010;30:681-7.
100. Hyams D, de Oliveira C, Snyder R, et al. Cediranib in combination with fulvestrant in hormonesensitive metastatic breast cancer: a phase II randomized study. Clin Cancer Res 2009;69(24 suppl): Abstract 204.
101. Andre F, Bachelot TD, Campone M, et al. A multicenter, open-label phase II trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1-amplified and nonamplified metastatic breast cancer (BC). Presented at the annual meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011.
102. Tolaney S, Nechushtan H, Berger R, et al. P1-17-10: Cabozantinib (XL184) in patients with metastatic breast cancer: Results from a phase 2 randomized discontinuation trial. Cancer Res 2012 (24 suppl);71:P1-17-10.
103. Schilsky R, Geary D, Skoog L et al. Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer. Targeted Oncol 2008;3: 3-11.
104. Chiorean EG, Malireddy S, Younger AE et al. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010;66:441-448.
105. Eder JP, Shapiro GI, Appleman LJ et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-3516.
106. Mackey J, Gelmon K, Martin M et al. TRIO-012: A multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer 2009;9:258-261.
107. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-787.
108. Vahdat LT, Miller K, Sparano JA, et al. Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402). J Clin Oncol 2011; 29(15 suppl):Abstract TPS151.
109. Isambert N, Freyer G, Zanetta S et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2012;18:1743-1750.
110. Dieras V, Jassem J, Dirix LY, et al. A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). J Clin Oncol 2011;29(15 suppl): Abstract 544. cancer: The E2100 outlier. Lancet Oncol 2010;11:1117-1119.
111. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20:S56-S60.
112. Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011;365:e3.
113. Sekeres MA. The Avastin story. N Engl J Med 2011;365:1454-1455.
114. Pazdur R. Endpoints for assessing drug activity in clinical trials. The Oncologist 2008;13:19-21.
115. Saad ED, Katz A, Hoff PM et al. Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12.
116. Dodd LE, Korn EL, Freidlin B et al. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol 2008;26:3791-3796.
117. D'Agostino RB, Sr. Changing end points in breast-cancer drug approval:the Avastin story. N Engl J Med 2011;365:e2.
118. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-2621.
119. Ebos JM, Lee CR, Cruz-MunozWet al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15: 232-239.
120. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
121. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-221.
122. Miles D, Harbeck N, Escudier B et al. Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-88.
123. Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16.
124. Schneider BP, Sledge GW, Jr. Anti-vascular endothelial growth factor therapy for breast cancer: Can we pick the winners? J Clin Oncol 2011;29:2444-2447.
125. Chustecka Z. Avastin for breast cancer: FDA answer is still no. Available at: http://www.medscape.com/ viewarticle/745590. Accessed November 20, 2011.
126. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
127. Vidal M, Di Cosimo S, Torrejon D et al. Survival outcome with bevacizumab: Activation of the phosphatidylinositol-3 kinase (PI3K) pathway due to PIK3CA mutations or PTEN loss makes a difference. Cancer Res 2012;71(24 suppl):Abstract P5-13-01.
128. Rini BI, Garcia JA, Cooney MM et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-6283.
129. Vidal M, Di Cosimo S, Torrejon D et al. Survival outcome with bevacizumab: Activation of the phosphatidylinositol-3 kinase (PI3K) pathway due to PIK3CA mutations or PTEN loss makes a difference. Cancer Res 2012;71(24 suppl):Abstract P5-13-01.
130. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439.
131. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-3714.
132. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-3748.
133. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-86.